Summary
T and B lymphocyte functions were investigated in the course of a long-term trial of recombinant human erythropoietin in patients with progressing multiple myeloma. Peripheral mononuclear cell as well as T and B lymphocyte cultures were established at the 1st, 13th, and last week of the 24-week protocol from 16 treated and 15 untreated patients. Control cultures from healthy individuals were also obtained. A suppression of phytohemagglutinin-induced proliferation of T cells was noted in all 1st-week cultures, whereas a variable increase of3H-thymidine uptake was noted at the end of the trial in the cultures from erythropoietin-treated patients. A significant increase was observed, however, in cultures from 5 erythropoietin-treated patients who also received α-interferon when their cells were grown in the presence of the hormone. In contrast, the pokeweed mitogen-driven in vitro synthesis of immunoglobulins was not significantly influenced by the duration of erythropoietin treatment, nor by addition of the hormone. IgG secretion by Epstein-Barr virus-transformed B cells in cultures from 9 erythropoietin-treated and 6 untreated patients was enhanced in the presence of both recombinant human erythropoietin and α-interferon. These data suggest that synergy between the two cytokines may variably modulate certain immune functions in vitro. This effect might account for the increase of serum IgM levels noted in some patients who received α-interferon.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rennick D, Jackson J, Yang G, Wideman J, Lee F, Hudak S. Interleukin-6 interacts with interleukin-4 and other hematopoietic growth factors to selectively enhance the growth of megakaryocytic, erythroid, myeloid and multipotential progenitor cells. Blood 1989; 73:1828.
Valent P, Schmidt G, Besemer J, Mayer P, Zenke G, Liehl E, Hinterberger W, Lechner K, Maurer D, Bettelheim P. Interleukin-3 is a differentiation factor for human basophils. Blood 1989; 73:1763.
Ishibashi T, Koziol JA, Burnstein SA. Human recombinant erythropoietin promotes differentiation of murine megakaryocytes in vitro. J. Clin Invest 1987; 79:286.
Clark DA, Dessypris EN. Effects of recombinant erythropoietin on murine megakaryocytic colony formation in vitro. J Lab Clin Med 1986; 108:423.
Nishi N, Nakahata T, Koike K, Takagi M, Naganuma K, Akabane T. Induction of mixed erythroid-megakaryocyte colonies and bipotential blast cell colonies by recombinant human erythropoietin in serum-free cultures. Blood 1990; 76:1330.
Kimata H, Yoshida A, Ishioka C, Masuda S, Sakaki R, Mikawa H. Human recombinant erythropoietin directly stimulates B cell immunoglobulin production and proliferation in serum-free medium. Clin Exp Immunol 1991; 85–151.
Kimata H, Yoshida A, Ishioka C, Mikawa H. Erythropoietin enhances immunoglobulin production and proliferation by human plasma cells in a serum-free medium. Clin Immunol Immunopathol 1991; 59:495.
Grimm PC, Sinai-Trieman L, Sekiya NM, Robertson LS, Robinson BJ, Fine RN, Ettenger RB. Effects of recombinant human erythropoietin on HLA sensitization and cell mediated immunity. Kidney Int 1990; 38:12.
Imiela J, Korczak-Kowalska G, Malecki R, Nowaczyk M, Stepien-Sopniewska B, Gorski A. Immunomodulatory action of human recombinant erythropoietin in man. Immunol Lett 1993; 35:271.
Silvestris F, Romito A, Fanelli P, Vacca A, Dammacco F. Longterm therapy with recombinant human erythropoietin (rHu-EPO) in progressing MM. Ann Hematol; In press.
Schnaper HW, Aune TM, Pierce WC. Suppressor T cell activation by human leukocyte interferon. J Immunol 1983; 131:2301.
Territo M, Sarna G, Figlin R. Effect of in vitro administration of interferon upon monocyte function. J Biol Response Mod 1983; 2:450.
Creasey AA, Bartholomew JG, Merigan TC. Role of G0–G1 arrest in the inhibition of tumor cell growth by interferon. Proc Natl Acad Sci USA 1980; 77:1471.
Van Lier RAW, Brouwer M, Rebel VI, Van Noessel CJM, Aarden LA. Immobilized anti-CD3 monoclonal antibodies induce accessory cell-independent lymphokine production, proliferation and helper activity in human T lymphocytes. Immunology 1989; 68:45.
Eschbach JW, Haley NR, Egrie JC, Adamson JW. A comparison of the responses to rHu-EPO in normal and uremic subjects. Kidney Int 1992; 42:407.
Pfaffl W, Gross HJ, Neumeier D, Nattermann V, Samtleben W, Gurland HJ. Lymphocyte subsets and delayed cutaneous hypersensitivity in hemodialysis patients receiving recombinant human erythropoietin. Contrib Nephrol 1988; 66:195.
Grimm PC, Ettenger RB. The highest sensitized (high PRA) state is accompanied by high cellular anti-HLA immune responsiveness in dialysis patients (abstract). Proceedings of the 9th Annual Meeting of the American Society of Transplant Physicians, Chicago 29–31 May 1990; n. 42.
Pelton BJ, Denman AM. Immunoregulatory effects of interferon-α. Interferon-α inhibits in vitro antibody synthesis by normal human lymphocytes. Clin Exp Immunol 1985; 59:398.
Peters M, Ambrus JL, Zheleznyak A, Walling D, Hoofnagle JH. Effect of interferon α on immunoglobulin synthesis by human B cells. J Immunol 1986; 137:3153.
Janik JE, Sznol M, Urba WJ, Figlin R, Bukowski RM, Fyfe G, Pierce WC, Belldegrun A, Sharfman WH, Smith JW, Longo DL. Erythropoietin production. A potential marker for interleukin-2/interferon-responsive tumors. Cancer 1993; 72:2656.
Ihle JN, Qhelle FW, Miura O. Signal transduction through the receptor for erythropoietin. Semin Immunol 1993; 5:375.
Okuno Y, Takahashi T, Suzuki A, Ichiba S, Nakamura K, Hitomi K, Sasaki R, Imura R. Expression of the erythropoietin receptor on a human myeloma cell line. Biochem Biophys Res Commun 1990; 170:1128.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Silvestris, F., Savino, L., Tucci, M. et al. Immunomodulation of T and B cell functions in multiple myeloma patients treated with combined erythropoietin and α-interferon therapy. Int J Clin Lab Res 25, 79–83 (1995). https://doi.org/10.1007/BF02592361
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02592361